Miriam Th Harris1, Rebecca K Seliga2, Nadia Fairbairn3, Seonaid Nolan3, Alexander Y Walley4, Zoe M Weinstein4, Jeffery Turnbull5. 1. Grayken Center for Addiction, Boston Medical Center, One Boston Medical Center Pl, Boston, MA 02118, United States; Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, 801 Massachusetts Ave, Boston MA, 02118, United States. Electronic address: Miriam.Harris@bmc.org. 2. Ottawa University, Faculty of Medicine, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, ON K1H 8M5, Canada. 3. British Columbia Centre on Substance Use, 400-1045 Howe Street, Vancouver, BC, Canada, V6Z 2A9; Department of Medicine, University of British Columbia, St. Paul's Hospital, 553B-1081 Burrard Street, Vancouver, BC, Canada, V6Z 1Y6. 4. Grayken Center for Addiction, Boston Medical Center, One Boston Medical Center Pl, Boston, MA 02118, United States; Clinical Addiction Research and Education (CARE) Unit, Section of General Internal Medicine, Department of Medicine, Boston University School of Medicine and Boston Medical Center, 801 Massachusetts Ave, Boston MA, 02118, United States. 5. Ottawa University, Faculty of Medicine, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, ON K1H 8M5, Canada; Ottawa Inner City Health, 5 Myrand Ave, Ottawa, ON K1N 5N7, Canada.
Abstract
BACKGROUND: The Ottawa Inner City Health's Managed Opioid Program is the first, to our knowledge, to pair injectable opioid agonist hydromorphone treatment with assisted housing for people experiencing homelessness with severe opioid use disorder (OUD) and injection drug use. We aimed to describe this program and evaluate retention, health, and social wellbeing outcomes. METHODS: We retrospectively assessed the first cohort of clients enrolled in the Managed Opioid Program between August 2017-2018. The primary outcome was retention at 12 months. Secondary outcomes included injectable and oral opioid dose titration, non-prescribed opioid use, overdoses, connection with behavioural health services, and social well-being. Descriptive statistics were used to summarize baseline demographics and secondary outcomes. Actuarial survival analysis was used to assess retention among participants. RESULTS: The study sample included 26 participants: median age was 36 years, 14 were female, 22 were White, eight had alcohol use disorders, 25 had stimulant use disorders, and all had a history of concurrent psychiatric illness. Retention at 12 months was 77% (95% CI 62-95). Throughout the first-year participants' opioid treatment doses increased. The median daily dose of injectable hydromorphone was 36 mg [17-54 mg] and 156 mg [108-188 mg] at enrollment and one year respectively. The median daily dose of oral opioid treatment was 120-milligram morphine equivalents [83-180 mg morphine equivalents] and 330-milligram morphine equivalents [285-428 mg morphine equivalents] at enrollment and one year respectively. Over half had no overdoses and there were no deaths among participants who remained enrolled. At one year, 45% stopped non-prescribed opioid use, 96% connected to behavioral health services, 73% reconnected with estranged families, and 31% started work or vocational programs. CONCLUSION: Individuals with severe OUD engaged in injectable hydromorphone treatment and housing showed high retention in care and substantive improvements in patient-centered health and social well-being outcomes.
BACKGROUND: The Ottawa Inner City Health's Managed Opioid Program is the first, to our knowledge, to pair injectable opioid agonist hydromorphone treatment with assisted housing for people experiencing homelessness with severe opioid use disorder (OUD) and injection drug use. We aimed to describe this program and evaluate retention, health, and social wellbeing outcomes. METHODS: We retrospectively assessed the first cohort of clients enrolled in the Managed Opioid Program between August 2017-2018. The primary outcome was retention at 12 months. Secondary outcomes included injectable and oral opioid dose titration, non-prescribed opioid use, overdoses, connection with behavioural health services, and social well-being. Descriptive statistics were used to summarize baseline demographics and secondary outcomes. Actuarial survival analysis was used to assess retention among participants. RESULTS: The study sample included 26 participants: median age was 36 years, 14 were female, 22 were White, eight had alcohol use disorders, 25 had stimulant use disorders, and all had a history of concurrent psychiatric illness. Retention at 12 months was 77% (95% CI 62-95). Throughout the first-year participants' opioid treatment doses increased. The median daily dose of injectable hydromorphone was 36 mg [17-54 mg] and 156 mg [108-188 mg] at enrollment and one year respectively. The median daily dose of oral opioid treatment was 120-milligram morphine equivalents [83-180 mg morphine equivalents] and 330-milligram morphine equivalents [285-428 mg morphine equivalents] at enrollment and one year respectively. Over half had no overdoses and there were no deaths among participants who remained enrolled. At one year, 45% stopped non-prescribed opioid use, 96% connected to behavioral health services, 73% reconnected with estranged families, and 31% started work or vocational programs. CONCLUSION: Individuals with severe OUD engaged in injectable hydromorphone treatment and housing showed high retention in care and substantive improvements in patient-centered health and social well-being outcomes.
Authors: Heather Schacht Reisinger; Robert P Schwartz; Shannon Gwin Mitchell; James A Peterson; Sharon M Kelly; Kevin E O'Grady; Erica A Marrari; Barry S Brown; Michael H Agar Journal: J Psychoactive Drugs Date: 2009-09
Authors: Eugenia Oviedo-Joekes; Suzanne Brissette; Scott MacDonald; Daphne Guh; Kirsten Marchand; Salima Jutha; Scott Harrison; Amin Janmohamed; Derek Z Zhang; Aslam H Anis; Michael Krausz; David C Marsh; Martin T Schechter Journal: Drug Alcohol Depend Date: 2017-05-10 Impact factor: 4.492
Authors: John Strang; Teodora Groshkova; Ambros Uchtenhagen; Wim van den Brink; Christian Haasen; Martin T Schechter; Nick Lintzeris; James Bell; Alessandro Pirona; Eugenia Oviedo-Joekes; Roland Simon; Nicola Metrebian Journal: Br J Psychiatry Date: 2015-07 Impact factor: 9.319
Authors: Thilo Beck; Christian Haasen; Uwe Verthein; Stephan Walcher; Christoph Schuler; Markus Backmund; Christian Ruckes; Jens Reimer Journal: Addiction Date: 2014-01-19 Impact factor: 6.526
Authors: Sarah Konefal; Adam Sherk; Bridget Maloney-Hall; Matthew Young; Pam Kent; Emily Biggar Journal: BMC Public Health Date: 2022-02-10 Impact factor: 3.295
Authors: Thomas D Brothers; Malcolm Leaman; Matthew Bonn; Dan Lewer; Jacqueline Atkinson; John Fraser; Amy Gillis; Michael Gniewek; Leisha Hawker; Heather Hayman; Peter Jorna; David Martell; Tiffany O'Donnell; Helen Rivers-Bowerman; Leah Genge Journal: Drug Alcohol Depend Date: 2022-04-07 Impact factor: 4.852